Reflections on Disease: Understanding Identity, Physical Experience, and Clinical Management in Systemic Sclerosis
-
By
-
Neslihan Gokcen
-
June 23, 2026
By
Neslihan Gokcen
June 23, 2026
by Neslihan Gokcen
June 23, 2026
Once-weekly autoinjector approval was based on Phase 3 data, with safety consistent with intravenous administration.
April 28, 2026
The approval was based on reduced proteinuria, and an ongoing trial is required to determine whether atacicept slows long-term kidney function decline.
July 7, 2026